Strategies for reducing polypharmacy and other medication-related problems in chronic kidney disease

Seminars in Dialysis

Volumn 23, Issue 1, 2010, Pages 55-61

  Mason, Nancy A ^a   Bakus, Jodie L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC DISEASE; DRUG THERAPY; HUMAN; KIDNEY DISEASE; POLYPHARMACY;

CHRONIC DISEASE; DRUG THERAPY; HUMANS; KIDNEY DISEASES; POLYPHARMACY;

EID: 77950219802     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2009.00629.x     Document Type: Article

References (53)

1. Milton JC, Jackson SHD. Inappropriate polypharmacy: reducing the burden of multiple medications. Clin Med 2007, 7:514-517.
2. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 2005, 17:124-132.
3. Zarowitz BJ, Stebelsky LA, Muma BK, Romain TM, Peterson EL. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy 2005, 25:1636-1645.
4. McKinnon NJ, Hepler CD. Indicators of preventable drug-related morbidity in older adults. Use within a managed care organization. J Manag Care Pharm 2003, 2:134-141.
5. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the U.S. J Am Med Assoc 2008, 300:2867-2878.
6. Manley HJ, McClaran ML, Overbay DK, Wright MA, Reid GM, Bender WL, Neufeld TK, Hebbar S, Muther RS. Factors associated with medication-related problems in ambulatory hemodialysis patients. Am J Kidney Dis 2003, 41:386-393.
7. Strand LM, Morley PC, Cipolle RJ. Drug-related problems: their structure and function. Drug Intell Clin Pharm 1990, 24:1093-1097.
8. Gallagher P, Barry P, O'Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther 2007, 32:113-121.
9. Seniors at risk: designing the system to protect America's most vulnerable citizens from medication-related problems. http://www.ascp.com/publications/seniorsatrisk/, American Society of Consultant Pharmacists, Publication. 2004. Available at , accessed January 18, 2009
10. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc 2001, 41:192-199.
11. Lazarou J, Pomeranz BH, Corey PW. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J Am Med Assoc 1998, 279:1200-1205.
12. Manley HJ, Cannella CA, Bailie GR, St Peter WL. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis 2005, 46:669-680.
13. Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the emergency department: analysis of a high-risk population. Am J Emerg Med 1996, 14:447-450.
14. Committee on identifying and preventing medication errors: " medication errors: incidence and cost" Preventing Medication Errors: Quality Chasm Series 2006, 105-142. Aspden PAWolcott JABootman JLCronenwett LR. eds, In, Washington, Institute of Medicine of the National Academies, National Academies Press
15. Zhan D, Sangl J, Bieman AS, Miller MR, Friedman B, Wickizer SW, Meyer GS. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA 2001, 286:2823-2829.
16. Bailie GR, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, Wolfe R, Port F, Burrows-Hudson S, Saran R. Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. Nephrol Dial Transplant 2005, 20:1110-1115.
17. Eliason BC, Myszkowski J, Marbela A, Rasmann D. Use of dietary supplements by patients in a family practice clinic. J Am Board Fam Pract 1996, 9:249-253.
18. Hensrud DD, Engle DD, Scheitel SM. Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. Mayo Clin Proc 1999, 74:443-447.
19. Laliberte M, Normandeau M, Lamarre D, Cantin I, Berbiche D, Corneille L, Prud'homme L, Lalonde L. Use of over-the-counter medications and natural products in patients with moderate and severe chronic renal insufficiency. Am J Kidney Dis 2007, 49:245-256.
20. Hamrick I, Counts SH. Vitamin and mineral supplements. Prim Care 2008, 35:729-747.
21. Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Med Clin North Am 2005, 89:649-687.
22. Churchwell MD, Mueller BA. Selected pharmacokinetic issues in patients with chronic kidney disease. Blood Purif 2007, 25:133-138.
23. K/DOQI Workgroup: clinical practice guidelines for hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43(Suppl. 1):S1-S290.
24. Mason NA, Neudeck BL, Welage LS, Patel JA, Swartz RD. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration. Clin Nephrol 2003, 60:96-104.
25. Tang I, Vrahnos D, Hatoum H, Lau A. Effectiveness of clinical pharmacist interventions in a hemodialysis unit. Clin Ther 1993, 15:459-464.
26. Kaplan B, Mason NA, Shimp LA, Ascione FJ. Chronic hemodialysis patients. Part 1: Characterization and drug-related problems. Ann Pharmacother 1994, 28:316-318.
27. Kaplan B, Shimp LA, Mason NA, Ascione FJ. Chronic hemodialysis patients. Part 2: Reducing drug-related problems through application of the focused drug therapy review program. Ann Pharmacother 1994, 28:320-324.
28. Grabe DW, Bailie GR, Hanley HJ, Yeaw BF. The early patient-orientated care program as an educational tool and service. Am J Pharm Educ 1998, 62:279-284.
29. Manley HJ, Drayer DK, Muther RS. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. BMC Nephrol 2003, 4:10.
30. Grabe DW, Low CL, Bailie GR, Eisele G. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol 1997, 121:459-464.
31. Hirth RA, Greer SL, Albert JM, Young EW, Piette JD. Out-of pocket spending and medication adherence among dialysis patients in twelve countries. Health Aff 2008, 27:89-102.
32. Holley JL, DeVore CC. Why prescribed medications are not taken: results from a survey of chronic dialysis patients. Adv Perit Dial 2006, 22:162-166.
33. Kammerer J, Garry G, Hartigan M, Carter B, Erlich L. Adherence in patients on dialysis: strategies for success. Nephrol Nurs J 2007, 34:479-486.
34. Kutner NG. Improving compliance in dialysis patients: does anything work? Semin Dial 2001, 14:324-327.
35. Enhancing prescription medication adherence: a national action plan. http://www.talkaboutrx.org/, National Council on Patient Information and Education, Aug. 2007. Available at , accessed January 26, 2009
36. Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 2008, 9:2.
37. Haynes RB, Ackloo E, Sahota N, MacDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008, 2:CD000011.
38. Lawrence DB, Allison W, Chen JC, Demand M. Improving medication adherence with a targeted technology-driven disease management intervention. Dis Manag 2008, 11:141-144.
39. Manley HJ, Drayer DK, McClaran M, Bender W, Muther RS. Drug record discrepancies in an outpatient electronic medical record: frequency, type, and potential impact on patient care at a hemodialysis center. Pharmacother 2003, 23:231-239.
40. Ledger S, Choma G. Medication reconciliation in hemodialysis patients. Can Assoc Nephrol Nurse Technol J 2008, 18:41-43.
41. Lalonde L, Normandeau M, Lamarre D, Lord A, Berbiche D, Corneille L, Prud'homme L, Laliberte M. Evaluation of a training and communication-network nephrology program for community pharmacists. Pharm World Sci 2008, 30:924-933.
42. Patel HR, Pruchnicki MC, Hall LE. Assessment for chronic kidney disease service in high-risk patients at community health clinics. Ann Pharmacother 2005, 39:22-27.
43. Leal S, Soto M. Chronic kidney disease risk reduction in a Hispanic population through pharmacist-based disease-state management. Adv Chronic Kidney Dis 2008, 15:162-167.
44. Pharmacy program with disease management component targets CKD: navigator catches patients before dialysis. Dis Manag Advis 2008, 14:S8.
45. St Peter WL, Schoolwerth AC, McGowan T, McClellan WM. Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomes. Am J Kidney Dis 2003, 41:903-924.
46. RPA position on development of effective collaborative practice models for chronic renal care. Clin Nephrol 2001, 56:255-256.
47. Joy MS, Candiani C, Vaillancourt BA, Chin H, Hogan SL, Falk RJ. Reengineering clinical operations in a medical practice to optimize the management of anemia in chronic kidney disease. Pharmacotherapy 2007, 27:734-744.
48. To LL, Stoner CP, Stolley SN, Buenviaje JD, Ziegler TW. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit. Am J Health Syst Pharm 2001, 58:2061-2065.
49. Joy MS, DeHart RM, Gilmartin C, Hachey DM, Hudson JQ, Pruchnicki M. Clinical pharmacists as multidisciplinary health care providers in the management of CKD: a joint opinion by the nephrology and ambulatory care practice and research networks of the American College of Clinical Pharmacy. Am J Kidney Dis 2005, 45:1105-1118. Practice and Research Networks of the American College of Clinical Pharmacy
50. Manley HJ, Carroll CA. The clinical and economic impact of pharmaceutical care in end-stage renal disease patients. Semin Dial 2002, 15:45-49.
51. Kroenke K. Polypharmacy. Causes, consequences and cure. Am J Med 1985, 79:149-152.
52. Bent S, Padula A, Avins AL. Brief communication. Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med 2006, 144:257-261.
53. Zelikovsky N, Schast A. Eliciting accurate reports of adherence in a clinical interview: development of the medical adherence measure. Pediatr Nurs 2008, 34:141-146.